Xlear
CapsCanada
MenaQ7 Vitamin K2

NattoPharma Combines Ingredients with Hofseth BioCare

by Cristina Goodwin | February 26, 2015

NattoPharma ASA and Hofseth BioCare (HBC) have joined together and combined their clinically researched and validated ingredients, including MenaQ7 Vitamin K2 as MK-7 and OmeGo EFA from Salmon Oil, in order to create new products for heart health, specifally one that improves arterial elasticity while reducing oxLDL GP, a new cardiovascular marker.

NattoPharma’s new ingredient, MenaQ7 PURE, is a nature-identical synthetic vitamin K2 as menaquinone-7 (MK-7), and produced in a European pharmaceutical manufacturing facility and is fully validated by numerous human clinical studies, as well as in-vivo and in-vitro research; and is recognized by the world’s leading experts in vitamin K2 at University of Maastricht (Netherlands) for purity and quality. While HBC has recently introduced its OmeGo, a 100 percent traceable, sustainably-sourced salmon oil balanced EFA that, thanks to the company’s 24-hour production cycle and patented extraction process, is the freshest fish oil on the market today, according to HBC.

The companies’ will launch their first unique formula in the U.S., which is backed by NattoPharma’s U.S. Patent for the use of K2 in food products for heart health, as well as a Canadian Patent for the use of K2 with omega-3 fatty acids to support optimum bone, cartilage and cardiovascular health.

NattoPharma CEO, Hogne Vik said, “Omega-3 has been established as a cardiovascular health ingredient, as it has earned a qualified Health Claim in the U.S. for the reduction in risk of Coronary Heart Disease. Meanwhile, MenaQ7 Vitamin K2 as MK-7 has been clinically shown to increase arterial flexibility by promoting the most potent inhibitor of arterial calcification: the activation of Matrix Gla Protein (MGP).” “By balancing calcium metabolism, vitamin K2 offers a potential synergistic role with omega-3 that could result in unsurpassed cardiovascular formulas that also deliver bone health benefits.”

The companies rely on clinical trials as necessary for proving that their ingredients are more than effective. To that end, HBC has substantiated OmeGo Salmon Oil’s ability to lower a new and better marker of cardiac event predictability.

“There is emerging substantiated evidence that a new marker, oxLDL Beta 2 Glycoprotein Complex 1 (oxLDL GP), is directly tied to the risk of having a cardiac event, and the scientific community agrees it is a better marker of cardiac event predictability than cholesterol and/or triglycerides,” said Matt Mixter, managing director – U.S. for HBC. “Our human trials produced evidence substantiating OmeGo’s ability to lower this marker, which is a highly differentiable market position compared to commodity grade oils affecting less relevant markers.”

Senior Vice President of Global Sales and Marketing with NattoPharma, Eric Anderson added, “As MenaQ7 is the MK-7 form of vitamin K2, it is the most bioavailable K2 available. This means MK-7 supplementation only needs to be taken once a day and is, therefore, more convenient. And thanks to HBC’s proprietary, enzymatic hydrolysis process, consumers have the convenience of taking the equivalent of a serving of fresh fish every day in capsule that delivers no unpleasant side effects.”

For more information, visit www.nattopharma.com or www.hofsethbiocare.no.

Don't Miss Out!

Sign up for Vitamin Retailer Digital Newsletter
Digital Newsletter
Subscribe to Vitamin Retailer Magazine
Vitamin Retailer Magazine

Industry Professionals
Stay Informed!

Stay informed about the latest health, nutrition, and wellness developments by signing up for a FREE subscription to Vitamin Retailer magazine and digital newsletter.

Once subscribed, you will receive industry insights, product trends, and important news directly to your doorstep and inbox.

Subscribe To Our Newsletter

Stay Informed! Breaking news, industry trends featured topics, and more.

Subscribe to our newsletter today!